Clinical Trial Update: A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia [Phase 2]

View source ↗

Summary

Phase 2 trial update for AK102, a PCSK9 inhibitor, in patients with hypercholesterolemia; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• AK102

Snippet

Sponsor: Akeso | Conditions: Hypercholesterolemia | Phase 2 | Status: COMPLETED